乌诺前列酮
| 中文名称 | 乌诺前列酮 |
|---|---|
| 中文同义词 | 乌诺前列酮 1KG;化合物 T13955;化合物 UNOPROSTONE;Unoprostone(solution in acetate) |
| 英文名称 | UNOPROSTONE |
| 英文同义词 | UNOPROSTONE;9ALPHA, 11ALPHA-DIHYDROXY-15-OXO-20A,20B-DIHOMOPROST-5-EN-1-OIC ACID;Unii-6X4F561V3w;Unoprostone [inn];13,14-DIHYDRO-15-KETO-20-ETHYL PROSTAGLANDIN F2ALPHA;(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoic acid;5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)-;Alprostadil Impurity 20 |
| CAS号 | 120373-36-6 |
| 分子式 | C22H38O5 |
| 分子量 | 382.53 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 120373-36-6.mol |
| 结构式 |  |
乌诺前列酮 性质
| 沸点 | 562.9±40.0 °C(Predicted) |
|---|---|
| 密度 | 1.069±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMF：25 mg/ml； DMSO：17 mg/ml；乙醇：12 mg/ml； PBS（7.2）：90微克/毫升 |
| 形态 | Liquid |
| 酸度系数(pKa) | 4.76±0.10(Predicted) |
| 颜色 | Colorless to light yellow |
Pretreatment with Unoprostone (0.01, 0.1, 1 μM; 1 h before H
2
O
2
treatment) protects against H
2
O
2
-induced cell death in a concentration-dependent manner and the effect is significant at 0.1 μM and 1 μM concentrations.
Pretreatment with Unoprostone at concentrations of 0.1 to 3 μM protects against light-induced cell death in a concentration-dependent manner; the effect is significant at the 1 and 3 μM concentrations. Unoprostone reduces the morphological change, and it significantly inhibits the low mitochondrial membrane potential and cell death induced by light irradiation.
Unoprostone has prostaglandin F
2α
receptors (FP) binding affinity with a K
i
of 3.86 μM.
Cell Viability Assay
| Cell Line: | H 2 O 2 -induced photoreceptor cell |
| Concentration: | 0.01, 0.1, 1 μM |
| Incubation Time: | 1 hour before H 2 O 2 treatment |
| Result: | Protected against H 2 O 2 -induced cell death in a concentration-dependent manner. |
Unoprostone (0.06%, 0.12%; topical instillation; 3 µl) reduces mouse intraocular pressure (IOP) in a dose-dependent manner.
| Animal Model: | Male mice (6 weeks old) |
| Dosage: | 0.06%, 0.12% |
| Administration: | Topical instillation; 3 µl |
| Result: | Reduced mouse IOP in a dose-dependent manner. |